Trials / Completed
CompletedNCT01662414
Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease
Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Chulalongkorn University · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, placebo-controlled, Phase IV trial , comparing HMS 90® versus placebo (soy protein) as add-on (adjuvant) therapy in subjects with idiopathic Parkinson's Disease. The principal objective is to evaluate the changes in biomarkers of oxidative stress and,plasma amino acids, as well as improvement of clinical symptoms and brain function
Conditions
- Parkinson Disease
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Movement Disorders
- Neurodegenerative Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Whey protein | 1 sachect (10 g) 2times/ day |
| DIETARY_SUPPLEMENT | Soy protein | 1 sachect (10g) 2times/day |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2012-08-10
- Last updated
- 2013-09-30
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT01662414. Inclusion in this directory is not an endorsement.